Patents for A61P 35 - Antineoplastic agents (221,099)
04/2010
04/14/2010EP2174955A1 Ifnar2 muteins, their production and use
04/14/2010EP2174954A1 Hematopoietic cell e-selection/l-selectin ligand polypeptides and methods of use thereof
04/14/2010EP2174953A1 Compositions and methods for the diagnosis and treatment of tumor
04/14/2010EP2174939A1 Pyranones useful as ATM inhibitors
04/14/2010EP2174936A1 PNA monomer and precursor
04/14/2010EP2174930A1 Antitumor agent comprising sulfostin and sulfostin-related compound as the active ingredient
04/14/2010EP2174659A1 Substituted indeno[1,2-c]isoquinoline derivatives and uses thereof
04/14/2010EP2174651A1 A polymer-free hydrogel
04/14/2010EP2173908A2 Ultraconserved regions encoding ncrnas
04/14/2010EP2173876A2 T-cell cytokine-inducing surface molecules and methods of use
04/14/2010EP2173748A2 Indolyl pyrrolidines for the treatment of cancer
04/14/2010EP2173739A1 Substituted cc-1065 analogs and their conjugates
04/14/2010EP2173734A2 Chemical compounds
04/14/2010EP2173733A2 Compositions and methods comprising analogues of radicicol a
04/14/2010EP2173732A2 Docetaxel process and polymorphs
04/14/2010EP2173728A2 Heterocyclic modulators of pkb
04/14/2010EP2173724A2 Quinazolinone compounds and methods of use thereof
04/14/2010EP2173723A1 Pyrimidyl cyclopentanes as akt protein kinase inhibitors
04/14/2010EP2173722A2 Pyrimidine derivatives useful for the treatment of inflammatory or allergic conditions
04/14/2010EP2173438A2 Treatments and diagnostics for cancer, inflammatory disorders and autoimmune disorders
04/14/2010EP2173354A1 Quinoxaline derivatives as pi3 kinase inhibitors
04/14/2010EP2173352A2 Inhibitors of akt/pkb with anti-tumor activity
04/14/2010EP2173339A1 Campsiandra angustifolia extract and methods of extracting and using such extract
04/14/2010EP2173337A2 Phosphaplatins and their use in the treatment of cancers resistant to cisplantin and carboplatin
04/14/2010EP1786439B1 Methods of activating nkt cells
04/14/2010EP1627871B1 Cyclic aminophenyl sulfamate derivative
04/14/2010EP1477482B1 Novel phenylalanine derivative
04/14/2010EP1458414B1 Use of thrombin inhibitors coupled to polyalkylene glycol in tumour therapy
04/14/2010EP1406928B1 Ntb-a, a surface molecule involved in natural killer cells activity
04/14/2010EP1399483B1 Antibodies to insulin-like growth factor i receptor
04/14/2010EP1347773B1 Compositions and methods for enhancing cytokine activity and treating hypotension associated with the administration of cytokines
04/14/2010EP1294922B1 Treating cancer using organelle crystallizing agents
04/14/2010EP1221969B1 Activation of antigen-specific t cells by virus/antigen-treated dendritic cells
04/14/2010EP1207199B1 Tumor antigen
04/14/2010EP0961833B1 Human plasma hyaluronidase
04/14/2010EP0831903B1 Connective tissue growth factor
04/14/2010CN1994277B Solid preparation of salvianolic acid A of red sage root and preparation process thereof
04/14/2010CN1767852B Antibody vaccine conjugates and uses therefor
04/14/2010CN1593402B Application of di-amino di-indoly cyclo-nonanoyl imide in the process for preparing anti-tumor medicine
04/14/2010CN101694497A Methods of delivery of exogenous proteins to the cytosol and uses thereof
04/14/2010CN101693742A anti-igf-i receptor antibody
04/14/2010CN101693709A Bicyclic amides as kinase inhibitors
04/14/2010CN101693688A Indeno isoquinolone derivatives, preparation process and medical application thereof
04/14/2010CN101693670A Benzoic acid nitrogen mustard derivative as well as preparation method and application thereof
04/14/2010CN101693112A Deoxypodophyllotoxin cyclodextrin inclusion compound, preparation method and antitumor application thereof
04/14/2010CN101693097A Medicament for adjuvant therapy of tumors and preparation method thereof
04/14/2010CN101693096A Medicament for treating liver cancer and preparation method thereof
04/14/2010CN101693071A Medicament for adjuvant therapy of solid tumors and preparation method thereof
04/14/2010CN101693035A Medicinal preparation with inhibiting effect on tumor metastasis
04/14/2010CN101693031A Inhibitors of the mutant form of KIT
04/14/2010CN101693024A Radionuclide-labelled biodegradable bioabsorbable biopolymer nano fibrous membrane, preparation process and application thereof
04/14/2010CN101693011A Preparation method of magnetic medicine-carrying nano-particle
04/14/2010CN101280317B FAK and EGFR targeted RNA interference plasmid-lipidosome antineoplastic complex
04/14/2010CN101235066B Novel toosendan fruit peel extract
04/14/2010CN101225070B Antineoplastic medicament
04/14/2010CN101129353B Use of 7-hydroxyl-3-[(4-hydroxyl)-3-(3-methyl- butyl-2- alkenyl) phenyl]-4H-1-benzopyran-4-ket
04/14/2010CN101091799B Medicine in use for treating gastric cancer, and preparation method
04/14/2010CN101077349B Total alkaloids of subprostrate sophora root soft capsules and preparation method and application thereof
04/13/2010US7696365 Heterocyclic compounds useful as malonyl-CoA decarboxylase inhibitors
04/13/2010US7696332 Replication vector showing cell-specific expression
04/13/2010US7696331 parenterally administering a dose of samarium ethylenediaminetetramethylenephosphonic acid (EDTMP); and carboplatin or taxoids; anticarcinogenic, antitumor, and antantiproliferative agents; autoimmune, infectious , metabolic or genetic disorders
04/13/2010US7696321 Molecules and methods for inhibiting shedding of KIM-1
04/13/2010US7696313 Prodrug compounds with isoleucine
04/13/2010US7696247 Lipid-based nitric oxide donors
04/13/2010US7696246 Useful in female hormone replacement therapy and as modulators of fertility; therapy of dysfunctional uterine bleeding, dysmenorrhea, endometriosis, leiomyomas (uterine fibroids), hot flashes, mood disorders, meningiomas, cancer; 6-(bis-2,2,2-Trifluoroethyl)amino-4-trifluoromethylcoumarin
04/13/2010US7696224 Phenylurea derivatives as inhibitors of tyrosine kinases for the treatment of tumour diseases
04/13/2010US7696214 Confining solid tumors; administering a tyrosine kinase inhibitor as antitumor agents; 4-(6-chloro-2,3-methylenedioxyanilino)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-tetrahydropyran-4-yloxyquinazoline
04/13/2010US7696213 2-amino-8-(trans-4-hydroxycyclohexyl)-4-methyl-7-oxo-N-1H-pyrazol-5-yl-7,8-dihydropyrido[2,3-d]pyrimidine-6-carboxamide; anticarcinogenic; phosphoinositide 3-kinase alpha (PI3-K alpha ) inhibitor; cell cycle regulation, proliferation, apoptosis; inhibit resistance to cytotoxic agents in cancer cells
04/13/2010US7696180 Antisense oligonucleotide derivative as antitumor agent; biodrugs
04/13/2010US7696172 culture product produced by culturing a recombinant host cell under suitable conditions to express the polypeptide; has an oncogenic activity; treating liver disorder cirrhosis, or pancreas disorder
04/13/2010US7696159 Treatment for basal cell carcinoma
04/13/2010US7696156 Human hemojuvelin (HJV) or dragon-like 1 (DL-1) polypeptides and variants and uses thereof
04/13/2010US7696155 Hemojuvelin or dragon-like 2 (DL-2) polypeptides and variants and uses thereof
04/13/2010US7696149 Peptides present in form of acetate, gluconate, glucuronate, lactate, citrate, ascorbate, benzoate or phosphate salts and administration forms also contain one of above acids as free acids; for treating sex hormone-dependent diseases
04/13/2010US7695720 target VEGFR2 (KDR/flk-1); for treating and preventing tumors
04/13/2010US7695715 Monoclonal antibodies, antigens and diagnosis and therapy of malignant diseases
04/13/2010CA2486001C Injectable pharmaceutical compositions of an anthracenedione derivative with anti-tumoral activity
04/13/2010CA2472280C Cytotoxic cyplasin of the sea hare, aplysia punctata, cdna cloning and expression of bioreactive recombinants
04/13/2010CA2432303C Pyrazole compounds useful as protein kinase inhibitors
04/13/2010CA2431308C Regulation of angiogenesis with zinc finger proteins
04/13/2010CA2430363C Compounds and their uses
04/13/2010CA2422377C Pyrazole compounds useful as protein kinase inhibitors
04/13/2010CA2408707C Compositions and methods for the treatment of cancer
04/13/2010CA2399208C Nucleoside analogs with carboxamidine modified monocyclic base
04/13/2010CA2383372C Cell-specific and/or tumor-specific promoter retargeting of herpes gamma 34.5 gene expression
04/13/2010CA2380805C Improved topical medicaments and methods for photodynamic treatment of disease
04/13/2010CA2373634C Isophosphoramide mustard analogs and use thereof
04/13/2010CA2360680C Antioxidant compositions and methods for companion animals
04/13/2010CA2348773C Functional antagonists of hedgehog activity
04/13/2010CA2345809C 6-substituted pyrazolo[3,4-d]pyrimidin-4-ones useful as cyclin dependent kinase inhibitors
04/13/2010CA2263675C Compositions comprising an inducing agent and an anti-viral agent for the treatment of blood, viral and cellular disorders
04/13/2010CA2257357C Humanized antibodies with modified glycosylation
04/13/2010CA2200868C Cdr-grafted type iii anti-cea humanized mouse monoclonal antibodies
04/11/2010WO2010126137A1 Anti-cadherin antibody
04/08/2010WO2010040054A2 Methods for suppressing toll-like receptor activity
04/08/2010WO2010040051A2 Membrane resident peptide in anti-cancer peptides causes tumor cell necrosis rather than apoptosis of cancer cells
04/08/2010WO2010039997A2 Hematopoietic protection against chemotherapeutic compounds using selective cyclin-dependent kinase 4/6 inhibitors
04/08/2010WO2010039920A2 Boldine compounds for promoting bone growth
04/08/2010WO2010039832A1 Anti-notch2 antibodies and methods of use
04/08/2010WO2010039825A2 IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS